pharma · Type 1 Diabetes Mellitus · Prophylaxis of Renal Allograft Rejection · ELDN
Eledon Pharmaceuticals
Eledon Pharmaceuticals clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Irvine, USA
- Founded
- 2020
- Employees
- 42
- Programs
- 9
- Drugs
- 11
- Patents
- 0
Eledon Pharmaceuticals projects
9 ClinicalTrials.gov programs sponsored by Eledon Pharmaceuticals.
Eledon Pharmaceuticals has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AT-1501
Eledon Pharmaceuticals
Amyotrophic Lateral Sclerosis
1 trial -
AT-1501
Eledon Pharmaceuticals
IgA Nephropathy
1 trial -
AT-1501
Eledon Pharmaceuticals
Kidney Transplant Rejection
2 trials -
AT-1501
Eledon Pharmaceuticals
Prevention of Rejection in Kidney Transplant
1 trial -
AT-1501
Eledon Pharmaceuticals
Type 1 Diabetes Mellitus
1 trial -
AT-1501 IV Infusion
Eledon Pharmaceuticals
Brittle Type 1 Diabetes Mellitus
1 trial -
AT-1501-K209
Eledon Pharmaceuticals
Prophylaxis of Renal Allograft Rejection
1 trial -
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Eledon Pharmaceuticals
Type 1 Diabetes Mellitus
1 trial -
2025P000818
Eledon Pharmaceuticals
Kidney Failure
1 trial
Frequently asked questions
How many clinical projects does Eledon Pharmaceuticals have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.